

BEAM Alliance

Biotechs from Europe innovating in Anti-Microbial Resistance

<http://beam-alliance.eu/>

The Challenge


The emergence of multi-drug resistant bacteria presents a global public health crisis which demands the development of new antibiotics, preventive or alternative strategies, yet the R&D investment from large pharmaceutical companies is on the wane due to lack of attractiveness of investment in this therapeutic area.

Innovation is largely driven by biotech companies, and need to engage more extensively in supporting innovation with R&D stimulating policies and incentives.

Our Mission

The BEAM Alliance will work to **improve the regulatory, investment, and commercial environments** in Europe for research, development, approval and market viability of **new products combating antimicrobial resistance.**

Our Achievements so far



Speaking up at




and more to come...

One position paper

One workshop with the European Commission

The Alliance of 49 Biotechs from 12 European Countries



Would like to join to engage policy makers with us?
Contact contact@beam-alliance.eu.